Ca2+ sensitization and Ca2+ entry in the control of blood pressure and adrenergic vasoconstriction in conscious Wistar - Kyoto and spontaneously hypertensive rats

Journal of Hypertension

Volumn 31, Issue 10, 2013, Pages 2025-2035

  Behuliak, Michal ^a   Pintérová, Mária ^a   Bencze, Michal ^a   Petrová, Miriam ^b   Líšková, Silvia ^a,b   Karen, Petr ^a   Kuneš, Jaroslav ^a   Vaněčková, Ivana ^a   Zicha, Josef ^a  

^a INSTITUTE OF PHYSIOLOGY   (Czech Republic)

^b Faculty of Natural Sciences   (Slovakia)

Author keywords

Fasudil; Nifedipine; RhoA Rho kinase; Sympathetic vasoconstriction

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; CALCIUM; FASUDIL; NIFEDIPINE; NORADRENALIN; RHO KINASE; 1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; ADRENERGIC RECEPTOR; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL STIMULATING AGENT; DRUG DERIVATIVE; NITRIC OXIDE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CALCIUM TRANSPORT; CONTROLLED STUDY; DOSE RESPONSE; MESENTERIC ARTERY; NONHUMAN; PRIORITY JOURNAL; RAT; SENSITIZATION; SIGNAL TRANSDUCTION; SPONTANEOUSLY HYPERTENSIVE RAT; VASOCONSTRICTION; WISTAR KYOTO RAT; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; MALE; METABOLISM; TEMPERATURE;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; 3-PYRIDINECARBOXYLIC ACID, 1,4-DIHYDRO-2,6-DIMETHYL-5-NITRO-4-(2-(TRIFLUOROMETHYL)PHENYL)-, METHYL ESTER; ANIMALS; BLOOD PRESSURE; CALCIUM; CALCIUM CHANNEL AGONISTS; CALCIUM CHANNELS, L-TYPE; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MESENTERIC ARTERIES; NIFEDIPINE; NITRIC OXIDE; NOREPINEPHRINE; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RECEPTORS, ADRENERGIC; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN; TEMPERATURE; VASOCONSTRICTION;

EID: 84884401657     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328362adb3     Document Type: Article

References (40)

1. Head RJ. Hypernoradrenergic innervation: its relationship to functional and hyperplastic changes in the vasculature of the spontaneously hypertensive rat. Blood Vessels 1989; 26:1-20.
2. De Champlain J. Pre and postsynaptic adrenergic dysfunctions in hypertension. JHypertens 1990; 8 (Suppl 7):S77-S85.
3. Hermsmeyer K. Differences of calcium channels in vascular muscle in hypertension. Am J Hypertens 1991; 4:412S-415S.
4. Ohya Y, Tsuchihashi T, Kagiyama S, Abe I, Fujishima M. Single L-type calcium channels in smooth muscle cells from resistance arteries of spontaneously hypertensive rats. Hypertension 1998; 31:1125-1129.
5. Cox RH, Rusch NJ. New expression profiles of voltage-gated ion channels in arteries exposed to high blood pressure. Microcirculation 2002; 9:243-257.
6. Sonkusare S, Palade PT, Marsh JD, Telemaque S, Pesic A, Rusch NJ. Vascular calcium channels and high blood pressure. pathophysiology and therapeutic implications. Vascul Pharmacol 2006; 44:131-142.
7. Pinterova M, Kunes J, Zicha J. Altered neural and vascular mechanisms in hypertension. Physiol Res 2011; 60:381-402.
8. Nelson MT, Standen MB, Brayden JE, Worley JF. Noradrenaline contracts arteries by activating voltage-dependent calcium channels. Nature 1988; 336:382-385.
9. Paulis L, Liskova S, Pinterova M, Dobesova Z, Kunes J, Zicha J. Nifedipine-sensitive noradrenergic vasoconstriction is enhanced in spontaneously hypertensive rats: the influence of chronic captopril treatment. Acta Physiol (Oxford) 2007; 191:255-266.
10. Pinterova M, Karen P, Kunes J, Zicha J. Role of nifedipine-sensitive sympathetic vasoconstriction in maintenance ofhigh blood pressure in spontaneously hypertensive rats: effect of Gi-protein inactivation by pertussis toxin. JHypertens 2010; 28:969-978.
11. Pinterova M, Liskova S, Dobesova Z, Behuliak M, Kunes J, Zicha J. Impaired control of L-type voltage-dependent calcium channels in experimental hypertension. Physiol Res 2009; 58 (Suppl 2):S43-S54.
12. Hill MA, Potocnik SJ, Martinez-Lemus LA, Meininger GA. Delayed arteriolar relaxation after prolonged agonist exposure: functional remodeling involving tyrosine phosphorylation. Am J Physiol Heart Circ Physiol 2003; 285:H849-H856.
13. Hilgers RH, Webb RC. Molecular aspects of arterial smooth muscle contraction: focus on Rho. Exp Biol Med (Maywood) 2005; 230:829835.
14. Wirth A. Rho kinase and hypertension. Biochim Biophys Acta 2010; 1802:1276-1284.
15. Nagumo H, Sasaki Y, Ono Y, Okamoto H, Seto M, Takuwa Y. Rho kinase inhibitor HA-1077 prevents Rho-mediated myosin phosphatase inhibition in smooth muscle cells. Am J Physiol Cell Physiol 2000; 278:C57-C65.
16. Asano T, Suzuki T, Tsuchiya M, Satoh S, Ikegaki I, Shibuya M, et al. Vasodilator actions of HA1077 in vitro and in vivo putatively mediated by the inhibition of protein kinase. Br JPharmacol 1989; 98:1091-1100.
17. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997; 389:990-994.
18. Asano M, Nomura Y. Comparison of inhibitory effects of Y-27632, a Rho kinase inhibitor, in strips of small and large mesenteric arteries from spontaneously hypertensive and normotensive Wistar-Kyoto rats. Hypertens Res 2003; 26:97-106.
19. Mukai Y, Shimokawa H, Matoba T, Kandabashi T, Satoh S, Hiroki J, et al. Involvement of Rho-kinase in hypertensive vascular disease: a novel therapeutic target in hypertension. FASEB J 2001; 15:10621064.
20. Lohn M, Steioff K, Bleich M, Busch AE, Ivashchenko Y. Inhibition of Rho-kinase stimulates nitric oxide-independent vasorelaxation. Eur J Pharmacol 2007; 507:179-186.
21. Dhaliwal JS, Casey DB, Greco AJ, Badejo AM Jr, Gallen TB, Murthy SN, et al. Rho kinase and Ca2+ entry mediate increased pulmonary and systemic vascular resistance in L-NAME-treated rats. Am JPhysiol Lung Cell Mol Physiol 2007; 293:L1306-L1313.
22. Casey DB, Badejo AM, Dhaliwal JS, Sikora JL, Fokin A, Golwala NH, et al. Analysis of responses to the Rho-kinase inhibitor Y-27632 in the pulmonary and systemic vascular bed of the rat. Am J Physiol Heart Circ Physiol 2010; 299:H184-H192.
23. Loirand G, Pacaud P. The role ofRho protein signaling in hypertension. Nat Rev Cardiol 2010; 7:637-647.
24. Alvarez SM, Miner AS, Browne BM, Ratz PH. Failure of Bay K 8644 to induce RhoA kinase-dependent calcium sensitization in rabbit blood vessels. Br J Pharmacol 2010; 160:1326-1337.
25. Janacek J, Prasil I. Quantification of plant frost injury by nonlinear fitting of an S-shaped function. Cryo-Lett 1991; 12:47-52.
26. Mischan MM, de Pinho SZ, de Carvalho LR. Determination of a point sufficiently close to the asymptote in nonlinear growth functions. Sci Agric 2011; 68:109-114.
27. Liskova S, Petrova M, Karen P, Kunes J, Zicha J. Influence of calcium-dependent potassium channel blockade and nitric oxide inhibition on norepinephrine-induced contractions in two forms of genetic hypertension. J Am Soc Hypertens 2010; 4:128-134.
28. Behuliak M, Kunes J, Zicha J. Age-related differences in blood pressure response to acute blockade ofcalcium influx and calcium sensitization in Wistar-Kyoto and spontaneouslyhypertensive rats. JHypertens2012; 30 (Suppl 1):e239. 2
29. Lozinskaya IM, Cox RH. Effects of age on Ca2+ currents in small mesenteric artery myocytes from Wistar-Kyoto and spontaneously hypertensive rats. Hypertension 1997; 29:1329-1336.
30. Takata Y, Howes LG, Hutchinson JS. Antihypertensive effect of diltia-zem in young or adult rats of genetically hypertensive strains. Clin Exp Hypertens A 1983; 5:455-468.
31. Lohn M, Plettenburg O, Ivashchenko Y, Kannt A, Hofmeister A, Kadereit D, et al. Pharmacological characterization of SAR407899, a novel Rho-kinase inhibitor. Hypertension 2009; 54:676-683.
32. Kast R, Schirok H, Figueroa-Perez S, Mittendorf J, Gnoth MJ, Apeler H, et al. Cardiovascular effects of a novel potent and highly selective azaindole-based inhibitor of Rho-kinase. Br J Pharmacol 2007; 152:1070-1080.
33. Wolfrum S, Dendorfer A, Rikitake Y, Stalker TJ, Gong Y, Scalia R, et al. Inhibition of Rho-kinase leads to rapid activation of phosphatidylino-sitol 3-kinase/protein kinase Akt and cardiovascular protection. Arte-rioscler Thromb Vasc Biol 2004; 24:1842-1847.
34. Kazda S, Garthoff B, Luckhaus G. Calcium and malignant hypertension in animal experiment: effects of experimental manipulation of calcium influx. Am JNephrol 1986; 6 (Suppl 1):145-150.
35. Kanda T, Wakino S, Hayashi K, Homma K, Ozawa Y, Saruta T. Effect of fasudil on Rho-kinase and nephropathy in subtotally nephrectom-ized spontaneously hypertensive rats. Kidney Int 2003; 64:20092019.
36. Nishikimi T, Koshikawa S, Ishikawa Y, Akimoto K, Inaba C, Ishimura K, etal. Inhibition of Rho-kinase attenuates nephrosclerosis and improves survival in salt-loaded spontaneously hypertensive stroke-prone rats. J Hypertens 2007; 25:1053-1063.
37. Shaw LM, Ohanian J, Heagerty AM. Calcium sensitivity and agonist-induced calcium sensitization in small arteries of young and adult spontaneously hypertensive rats. Hypertension 1997; 30:442-448.
38. Koshikawa S, Nishikimi T, Inaba C, Akimoto K, Matsuoka H. Fasudil, a Rho-kinase inhibitor, reverses L-NAME exacerbated severe nephro-sclerosis in spontaneously hypertensive rats. J Hypertens 2008; 26:1837-1848.
39. Ishikawa Y, Nishikimi T, Akimoto K, Ishimura K, Ono H, Matsuoka H. Long-term administration of Rho-kinase inhibitor ameliorates renal damage in malignant hypertensive rats. Hypertension 2006; 47:10751083.
40. Sauzeau V, Le Jeune H, Cario-Toumaniantz C, Smolenski A, Lohmann SM, Bertoglio J, et al. Cyclic GMP-dependent protein kinase signaling pathway inhibits RhoA-induced Ca2+ sensitization of contraction in vascular smooth muscle. JBiolChem2000 275:21722-21729